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A B S T R A C T
Background
World Health Organization (WHO) guidelines for monitoring HIV-infected individuals taking
combination antiretroviral therapy (cART) in resource-limited settings recommend using CD4þ
T cell (CD4) count changes to monitor treatment effectiveness. In practice, however, falling CD4
counts are a consequence, rather than a cause, of virologic failure. Adherence lapses precede
virologic failure and, unlike CD4 counts, data on adherence are immediately available to all
clinics dispensing cART. However, the accuracy of adherence assessments for predicting future
or detecting current virologic failure has not been determined. The goal of this study therefore
was to determine the accuracy of adherence assessments for predicting and detecting virologic
failure and to compare the accuracy of adherence-based monitoring approaches with
approaches monitoring CD4 count changes.
Methodology and Findings
We conducted an observational cohort study among 1,982 of 4,984 (40%) HIV-infected adults
initiating non-nucleoside reverse transcriptase inhibitor-based cART in the Aid for AIDS Disease
Management Program, which serves nine countries in southern Africa. Pharmacy refill
adherence was calculated as the number of months of cART claims submitted divided by the
number of complete months between cART initiation and the last refill prior to the endpoint of
interest, expressed as a percentage. The main outcome measure was virologic failure defined as
a viral load . 1,000 copies/ml (1) at an initial assessment either 6 or 12 mo after cART initiation
and (2) after a previous undetectable (i.e., , 400 copies/ml) viral load (breakthrough viremia).
Adherence levels outperformed CD4 count changes when used to detect current virologic
failure in the first year after cART initiation (area under the receiver operating characteristic
[ROC] curves [AUC] were 0.79 and 0.68 [difference ¼ 0.11; 95% CI 0.06 to 0.16; v2 ¼ 20.1]
respectively at 6 mo, and 0.85 and 0.75 [difference ¼ 0.10; 95% CI 0.05 to 0.14; v2 ¼ 20.2]
respectively at 12 mo; p , 0.001 for both comparisons). When used to detect current
breakthrough viremia, adherence and CD4 counts were equally accurate (AUCs of 0.68 versus
0.67, respectively [difference ¼ 0.01; 95% CI 0.06 to 0.07]; v2 ¼ 0.1, p . 0.5). In addition,
adherence levels assessed 3 mo prior to viral load assessments were as accurate for virologic
failure occurring approximately 3 mo later as were CD4 count changes calculated from cART
initiation to the actual time of the viral load assessments, indicating the potential utility of
adherence assessments for predicting future, rather than simply detecting current, virologic
failure. Moreover, combinations of CD4 count and adherence data appeared useful in
identifying patients at very low risk of virologic failure.
Conclusions
Pharmacy refill adherence assessments were as accurate as CD4 counts for detecting current
virologic failure in this cohort of patients on cART and have the potential to predict virologic
failure before it occurs. Approaches to cART scale-up in resource-limited settings should
include an adherence-based monitoring approach.
The Editors’ Summary of this article follows the references.
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Introduction
As the number of patients on combination antiretroviral
therapy (cART) grows worldwide, developing simple, afford-
able ways of monitoring patients after treatment initiation
has become a major public health priority. Since the central
paradigm of antiretroviral therapy is suppression of viral
replication, and since costs of second-line cART are higher
than ﬁrst-line regimens [1], monitoring efforts should, as
much as possible, focus on preserving the virologic effective-
ness of ﬁrst-line combinations. Failure to identify patients
who are at high risk of future virologic failure or who are
currently on partially suppressive regimens may result in
selection of viral resistance mutations, which have been
associated with more rapid disease progression and death [2–
4].
In the developed world, the standard of care for
monitoring virologic response involves measuring plasma
HIV-1 RNA levels (‘‘viral loads’’) [5]. These assays are often
unavailable in the developing world because of ﬁnancial
and technical constraints [6]. Since CD4þ T cell (CD4)
counts are comparatively inexpensive, World Health Or-
ganization (WHO) guidelines for scaling up antiretroviral
therapy in resource-limited settings advocate use of CD4
count criteria to identify patients on failing cART regimens
[7]. Thus, CD4 counts are considered an essential tool for
monitoring patients on cART [8], and there is a widespread
movement to incorporate cheaper, less technologically
demanding CD4 count assays into clinical care in the
developing world [9].
Quantifying and monitoring adherence to cART is one
potentially useful and low-cost method of identifying patients
at high risk for virologic failure in resource-limited settings
[10]. Adherence is strongly associated with virologic response
in a dose-dependent manner [11–16]. Furthermore, among
patients on ﬁrst-line therapy, lapses in adherence usually
precede immunologic declines and, unlike CD4 count data,
adherence data available to all clinics that dispense cART may
be simple to compile [10]. Furthermore, they directly measure
the variable on which providers can intervene. Thus,
adherence assessments focus on the cause rather than the
consequence of virologic failure and may enable guided
interventions capable of preventing virologic failure. There-
fore, although CD4 count monitoring in patients on cART is
deeply ingrained in HIV care [5,7], if adherence assessments
are as accurate as CD4 count changes for identiﬁcation of
patients with virologic failure, sites currently performing or
planning CD4 count measurements for this purpose could
instead choose to monitor adherence, thereby preserving
scarce resources for triaged virologic monitoring [17,18] or
other treatment-related activities.
Despite the potential time and cost savings of this method,
the diagnostic accuracy of various adherence levels for
predicting virologic failure has not been determined, and
current WHO guidelines for monitoring cART in resource-
limited settings include only general recommendations for
assessing adherence and no detail about the levels of
adherence that should trigger interventions [7]. To address
this information gap, we compared the diagnostic accuracy of
CD4 cell count changes and adherence measurements for
virologic failure on cART.
Methods
Study Design
The primary analysis of this observational cohort study
evaluated the relative abilities of pharmacy reﬁll adherence
and CD4 counts to detect current viral loads indicative of
treatment failure. Therefore the primary outcome of interest
was virologic failure, deﬁned as a viral load .1,000 copies/ml.
Assessments of this outcome were considered in two ways: (1)
lack of virologic response (deﬁned as a viral load .1,000
copies/ml) either 6 or 12 mo after cART initiation, and (2)
breakthrough viremia, as demonstrated by a follow-up viral
load .1,000 copies/ml after achievement of an undetectable
(i.e., , 400 copies/ml) viral load. Lack of response within the
ﬁrst year was chosen as an outcome because of the clinical
relevance of initial response to cART on subsequent disease
outcomes [19], and breakthrough viremia was chosen as an
outcome because several studies have reported that a
majority of patients initiating cART achieve viral loads ,
400 copies/ml within the ﬁrst year [19–22]. For the primary
analyses focused on detecting current virologic failure, the
available CD4 count and adherence data were analyzed up to
the time the provider was assessing the likelihood of virologic
failure. Sensitivity was deﬁned as the proportion of patients
with virologic failure who met certain CD4 count change or
adherence level criteria, and speciﬁcity was deﬁned as the
proportion of patients without virologic failure who did not
meet these criteria. Positive (negative) predictive value was
deﬁned as the probability that a patient meeting (not
meeting) certain CD4 count change or adherence level
criteria had (did not have) virologic failure at that time.
Breakthrough viremia was deﬁned as occurrence of virologic
failure at any time . 30 d after a prior undetectable viral
load.
Study Setting
We examined medical records from HIV-1–infected adults
enrolled in Aid for AIDS, a private health care management
program available to subscribers to medical insurance funds
in nine countries in southern Africa. Patient demographic
and clinical data and pharmacy drug information have been
recorded by Aid for AIDS since June 1998 and have been
described previously [12,20]. In brief, if HIV-infected patients
consent, baseline demographic and clinical data are recorded
in the electronic Aid for AIDS database at the time of patient
enrollment. After enrollment, individuals with CD4 counts ,
350 cells/ll or with an AIDS-deﬁning condition are eligible to
initiate cART. Patients submitting pharmacy claims are
reimbursed by their medical insurance fund for the cost of
drugs. All claims are processed through the coordinating
center at the Aid for AIDS Cape Town ofﬁce. Claims include
the drug names and date of the prescription reﬁll, and drugs
are dispensed in uniform increments of 30 d of an entire
cART regimen each time a prescription is reﬁlled. Differ-
ential delays between countries or sites within countries with
respect to returning prescriptions for processing are rare.
Study Participants
Patients who met the following general criteria were
eligible: (1) age  18 y; (2) pretreatment plasma viral load
level of . 2,000 copies/ml; (3) initiated non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based cART, a
criterion chosen because of its relevance to resource-limited
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settings [23,24] and deﬁned as an NNRTI plus two nucleoside
reverse transcriptase inhibitors; and (4) CD4 count and viral
load assessment within 90 d prior to or on the day of therapy
initiation. In addition, for the evaluation of treatment
response at 6 and 12 mo, patients needed: (1) a follow-up
CD4 count within 3–9 or 9–15 mo after initiating cART,
respectively, and (2) a follow-up viral load within 45 d of the
corresponding follow-up CD4 count. The analysis of break-
through viremia was limited to patients meeting general
criteria who also had (1) at least one undetectable viral load
obtained after cART initiation, (2) a subsequent follow-up
viral load obtained at least 30 d after the ﬁrst undetectable
viral load, and (3) a CD4 count obtained within at least 45 d of
this follow-up viral load. Patients could be included in one or
more analyses.
Data Collection
Decisions to monitor patients in Aid for AIDS are left up to
the patients’ physicians, and patient specimens are sent to a
variety of clinical laboratories, although physicians are
instructed to use the same laboratory for each patient.
WHO-advocated criteria of a CD4 count drop to pretreat-
ment levels or below, a CD4 count drop to 50% or less of
maximum on-therapy levels, and a CD4 count persistently
below 100 cells/ll as well as alternative CD4 count criteria,
were examined [7]. The analysis of a CD4 count decrease to
50% of maximum on-therapy levels was limited to the
analysis of breakthrough viremia, since this criterion implies
that previous CD4 count monitoring on therapy has been
done. The last viral load and corresponding CD4 count
available in the database were chosen as the endpoint values
for patients who did not have breakthrough viremia.
Pharmacy claims adherence data in this dataset have been
validated for virologic response and for survival [12,20].
Adherence was calculated as the number of months with
cART claims submitted, divided by the number of complete
months from cART commencement to the date of the
relevant study endpoint, and the result multiplied by 100, as
described [12,16]. Since patients ﬁll entire cART regimens
with each reﬁll, we tracked the entire regimen rather than
using an ‘‘index drug’’ approach, which tracks only a single
drug of a regimen.
Statistical Analysis
The primary goal of the analysis was to examine and
compare the ability of CD4 counts and adherence data to
detect current virologic failure, rather than to explore
etiologic associations with these outcomes. However, in order
ﬁrst to understand risk factors for virologic failure in the
patient population, we performed unadjusted and adjusted
analyses for this outcome. Differences in baseline character-
istics were assessed with two-sample t-tests or with Wilcoxon
rank sum tests (continuous variables), depending on the
distribution of the data, and Chi-square (v2) tests were used to
compare categorical variables. A relative risk for the primary
exposures (e.g., CD4 count criteria and adherence level) with
a 95% conﬁdence interval (CI) was determined and then
evaluated in multivariable logistic regression analysis (which
produced odds ratios [ORs]) to assess possible confounding.
Confounding was considered present if the unadjusted OR
changed by 15% or more after adjustment. However, in order
to evaluate whether the inclusion of possible confounders not
meeting this criterion in the analysis affected the study’s
ﬁndings, we also evaluated the results after forcing variables
plausibly associated with virologic failure in the multivariable
model [25]. For uniformity, all presented ORs are adjusted
values.
Overall diagnostic accuracy of adherence and CD4 count
changes were expressed using receiver operating character-
istic (ROC) curves and 95% CIs. Larger areas under the ROC
curve (AUC) indicate greater overall ability to discriminate
between patients with and without virologic failure. For tests
with binary outcomes (e.g., presence or absence of virologic
failure), the area under the ROC curve is equal to the c (for
concordance) statistic [26]. For binary endpoints, c-statistics
are the proportion of all pairs of patients, one with and one
without the outcome, in which the patient with the event had
a greater predicted probability of the outcome [27]. For
example, a coin toss would have a c-statistic of 0.5, whereas a
test with perfect discrimination would have a c-statistic of 1.0
[28]. The c-statistics were compared using Chi-square tests in
Stata version 9.0 (Intercooled) (STATA, College Station,
Texas). p-Values for the primary comparison of AUCs at 6
and 12 mo and for breakthrough viremia were not adjusted
for multiple comparisons. Furthermore, we used bootstrap
resampling to evaluate the robustness of our ﬁndings by
resampling with replacement observations from the original
dataset 999 times, which produced 95% CIs for the mean
difference in AUCs [29]. The sensitivity of our ﬁndings to the
deﬁnition of virologic failure was analyzed using a level of 
10,000 copies/ml as the outcome in secondary analyses. In
addition, AUCs for ROC curves derived from rules created
using speciﬁc criteria are presented to enable rapid evalua-
tion of overall diagnostic accuracy of each criterion with
respect to others, and to permit comparison of these ROC
areas with a reference test of a CD4 count decrease to
pretreatment levels or below. Since this process involved
multiple comparisons, these p-values were corrected for
multiple comparisons using Sidak’s method. Test character-
istics of each speciﬁc criterion were determined using logistic
regression.
Sub-analyses. We performed subanalyses to evaluate the
possibility that adherence assessments could be performed
months prior to the date of viral load measurements in order
to predict future, rather than detect current, virologic failure.
Speciﬁcally, we determined the accuracy of adherence
assessments performed approximately 3 mo prior to a viral
load assessment for virologic failure and compared this
estimate of accuracy with that resulting from assessments of
CD4 count changes calculated from the time of cART
initiation to the time the viral load was done (e.g., 3 mo
later). This was done for analyses of virologic failure at 6 and
12 mo, and statistically was performed by comparing AUCs as
in the primary analysis. A schematic of this approach is given
in Figure 1. We also examined whether use of days, rather
than months, to calculate adherence altered the discrimi-
natory ability of adherence assessments in these shorter
intervals.
In addition, combinations of CD4 count and adherence
data were assessed to determine whether combined ap-
proaches could be created that resulted in positive or
negative predictive values that were sufﬁciently high (e.g.,
95%) that providers could avoid viral load testing altogether.
The proportion of patients with or without current virologic
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failure at the time of assessment who met a speciﬁc criterion
was also determined to evaluate how applicable the criterion
would be in clinical practice. These results were analyzed by
computing the exact binomial 95% CIs for these test
characteristics and proportions and comparing these to
characteristics of adherence or CD4 count changes alone.
Regulatory Approvals
This study was approved by the University of Cape Town
Research Ethics Committee, by the Aid for AIDS Clinical
Advisory Committee and Board, Cape Town, South Africa, by
the Johns Hopkins Bloomberg School of Public Health’s
Committee on Human Research and by the University of
Pennsylvania Institutional Review Board. Data were analyzed
anonymously, and a waiver of informed consent was obtained
for the study.
Results
There were 5,723 adults who initiated cART and had
registration information included in the Aid for AIDS
database used in this study. Of these, 739 patients (13%)
initiated non-NNRTI-based regimens and were therefore
excluded. Of the remaining 4,984, 1,982 (40%) initiating
NNRTI-based cART between 20 December 2000 and 28
February 2003 had sufﬁcient paired CD4 count and viral load
data both at baseline and at follow-up to be included in at
least one of the analyses below. The pretreatment median
(interquartile range [IQR]) CD4 counts were slightly lower
among those who did not have sufﬁcient follow-up data (144
[61 to 223] versus 165 [75 to 241] cells/ll), and the median
(IQR) viral loads were similar (5.12 [4.6 to 5.6] among those
included versus 5.16 [4.7 to 5.6] log10 copies/ml among those
not included). All patients meeting inclusion criteria
described above were analyzed. Of 1,982 patients, 890 (45%)
initiated zidovudine, lamivudine, and efavirenz; 538 (27%)
initiated zidovudine, lamivudine, and nevirapine; 206 (10%)
initiated didanosine, stavudine, and an NNRTI; the remaining
348 (18%) initiated other three-drug, NNRTI-based regimens.
Detecting Virologic Failure at 6 and 12 Months
The analyses of response at 6 and 12 mo included 958 and
872 individual patients, respectively; 293 patients who met
inclusion criteria for both endpoints were included in both
analyses. Virologic failure was experienced by 235 of 958
(25%) patients at 6 mo and 229 of 872 (26%) patients at 12
mo according to our deﬁnition (Table 1). Factors associated
with virologic failure are shown in Table 1. The median (IQR)
number of days between cART initiation and follow-up CD4
count was 201 (158 to 241) at 6 mo and 353 (296 to 399) at 12
mo, and more than 95% of follow-up CD4 counts and viral
loads were done on the same day. CD4 cell count increases
were signiﬁcantly smaller for those experiencing virologic
failure (median [IQR] increase in cells/ll of 70 [6 to 145]
versus 142 [72 to 251] at 6 mo [z ¼ 8.4; p , 0.001, rank sum
test] and 51 [5 to 153] versus 184 [95 to 316] at 12 mo [z ¼
11.4; p , 0.001, rank sum test]). Adherence levels and CD4
count changes according to virologic response at 6 and 12 mo
are shown in Figures 2–5.
Adherence values had greater overall accuracy for detect-
ing current virologic failure at 6 and 12 mo compared to CD4
count changes (AUCs [95% CI] of 0.79 [0.76 to 0.83] versus
0.68 [0.64 to 0.72] at 6 mo and 0.85 [0.82 to 0.88] versus 0.75
[0.72 to 0.79] at 12 mo; v2 ¼ 20.1 and 20.2, respectively, p ,
0.001 for both comparisons] (Figures 6 and 7). The boot-
strapped 95% CIs for the differences between adherence and
CD4 count AUCs were 0.11 (0.06 to 0.16) at 6 mo and 0.10
(0.05 to 0.14) at 12 mo. The adherence level that would result
in the fewest unnecessary treatment changes if used at either
time point (i.e., , 50%) had greater overall ability to identify
patients with virologic failure than the CD4 count change
level with the highest speciﬁcity at 6 mo (i.e., a CD4 count
drop to pretreatment levels or below; v2 ¼ 6.6, p ¼ 0.01
comparing AUCs) and at 12 mo (i.e., CD4 cell counts , 100
cells/ll at baseline and follow-up; v2 ¼ 8.0, p , 0.001). The
superiority of adherence persisted if virologic failure was
deﬁned as a viral load . 10,000 copies/ml (6-mo AUC of 0.80
[0.75 to 0.84] versus 0.71 [0.66 to 0.76]; v2¼ 7.6, p¼ 0.005; 12-
Figure 1. Schematic Illustrating Intervals during Which Pharmacy Refill Data Were Assessed as Early Markers of Subsequent Virologic Failure
Adherence in the first 3 mo of cART was compared with the CD4 count change from cART initiation to the time of the 6-mo viral load. Adherence in the
first 3 mo after the 6-mo follow-up date was compared with the CD4 count change measured from baseline to the time of the 12-mo viral load.
doi:10.1371/journal.pmed.0050109.g001
PLoS Medicine | www.plosmedicine.org May 2008 | Volume 5 | Issue 5 | e1090780
Adherence Monitoring on cART
Table 1. Characteristics of Patients with and without Virologic Failure at 6 and 12 Months
Characteristic Group 6 Months after cART (n ¼ 958) 12 Months after cART (n ¼ 872)
Virologic Failurea
(n ¼ 235)
Adjusted Odds
Ratio (95% CI)
Virologic Failurea
(n ¼ 229)
Adjusted Odds
Ratio (95% CI)
Sex Female 142 of 621 (23%) Reference 130 of 548 (24%) Reference
Male 93 of 337 (28%) 1.37 (1.02–1.87) 99 of 324 (37%) 1.47 (1.07–2.01)
Age  35 y 112 of 399 (28%) Reference 115 of 389 (30%) Reference
. 35 y 123 of 559 (22%) 0.70 (0.52–0.95) 114 of 483 (24%) 0.72 (0.53–0.98)
Treatment naı¨ve Yes 198 of 849 (23%) Reference 167 of 717 (23%) Reference
No 37 of 109 (34%) 1.81 (1.17–2.82) 62 of 155 (40%) 1.30 (1.01–1.61)
Baseline CD4 count  100 cells/ll 85 of 338 (25%) Reference 71 of 259 (27%) Reference
. 100 cells/ll 150 of 620 (24%) 0.96 (0.69–1.32) 158 of 613 (26%) 1.07 (0.76–1.52)
Baseline HIV-1 RNA level  100,000 copies/ml 89 of 427 (21%) Reference 93 of 373 (25%) Reference
. 100,000 copies/ml 146 of 531 (28%) 1.45 (1.07–1.99) 136 of 499 (27%) 1.13 (0.80–1.60)
Adherence level . 90% 45 of 481 (9%) Reference 36 of 475 (8%) Reference
 90% 190 of 477 (40%) 6.48 (4.51–9.28) 193 of 397 (49%) 11.84 (7.94–17.64)
CD4 count drop to pretreatment
levels or below
No 181 of 854 (21%) Reference 162 of 768 (21%) Reference
Yes 54 of 104 (52%) 4.12 (2.70–6.31) 67 of 104 (64%) 7.25 (4.63–11.38)
Baseline and follow-up CD4
count , 100 cells/ll
No 191 of 869 (22%) Reference 193 of 820 (24%) Reference
Yes 44 of 89 (49%) 5.30 (3.28–8.54) 36 of 52 (69%) 7.58 (4.35–13.23)
aDefined as a viral load . 1,000 copies/ml.
doi:10.1371/journal.pmed.0050109.t001
Figure 2. Scatter Plot of Pharmacy Refill Adherence Levels at 6 Months after Starting cART for Patients with and without Virologic Failure
doi:10.1371/journal.pmed.0050109.g002
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mo AUC of 0.87 [0.84 to 0.90] versus 0.78 [0.75 to 0.82]; v2 ¼
14.6, p , 0.001). Test characteristics for CD4 count changes
and adherence levels when used as tests for virologic failure
in the ﬁrst year of cART are shown in Tables 2 and 3,
respectively.
Detecting Breakthrough Viremia after Initial Virologic
Suppression
A total of 1,101 patients met inclusion criteria for the
analysis of breakthrough viremia. Of these patients, 151
(14%) had breakthrough viremia after an initial undetectable
viral load (Table 4). The median (IQR) duration of follow-up
for these patients was 648 d (533 to 721 d), or approximately
1.75 y.
Only nine of 1,101 patients (1%) had CD4 cell count values
that were persistently below 100 cells/ll, and this criterion
was therefore not evaluated further. 54 (5%) and 42 (4%) of
patients experienced a CD4 cell count drop to pretreatment
levels or below, or to levels 50% or less than the maximum on
treatment value, respectively. Both criteria were strongly
associated with breakthrough viremia, as was adherence
(Table 4).
There was no signiﬁcant difference between adherence
values and CD4 count changes from maximum on-treatment
values to follow-up with respect to identiﬁcation of patients
with breakthrough viremia (AUCs [95% CIs], 0.68 [0.64 to
0.73] for CD4 counts versus 0.67 [0.62 to 0.72]; v2 ¼ 0.1, p .
Figure 3. Scatter Plot of CD4 Count Change (cells/ll) at 6 Months after
Starting cART for Patients with and without Virologic Failure
doi:10.1371/journal.pmed.0050109.g003
Figure 4. Scatter Plot of Pharmacy Refill Adherence Levels at 12 Months after Starting cART for Patients with and without Virologic Failure
doi:10.1371/journal.pmed.0050109.g004
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0.5). The bootstrapped 95% CI for the difference between
adherence and CD4 count AUCs was 0.01 (0.06 to 0.07). The
CD4 count criterion with the largest AUC was not signiﬁ-
cantly different from the adherence criteria with the largest
AUC (a CD4 count drop of 20% or more from maximum on-
treatment values versus an adherence level of , 90% [v2 ¼
0.0, p . 0.5]) (Table 5). Similar to above, altering the
deﬁnition of virologic failure did not signiﬁcantly change
the results (AUC [95% CI] 0.65 [0.58 to 0.72] versus 0.70 [0.65
to 0.76]; v2 ¼ 1.6, p ¼ 0.21).
Ability of Early Adherence Assessments to Identify
Patients with Virologic Failure
The AUC for pharmacy reﬁll adherence measured during
the initial 3 mo after cART initiation for virologic failure at 6
mo was 0.72 (0.68 to 0.75), which was smaller than that
resulting from the adherence assessment at 6 mo (v2¼ 31.8, p
, 0.01), but similar (0.72 for adherence versus 0.68 for CD4
count change; v2 ¼ 2.0, p ¼ 0.15) to that resulting from
evaluation of the change in the CD4 count over the ﬁrst 6 mo
of cART. The AUC for pharmacy reﬁll adherence measured
over a 3 mo period ending approximately 3 mo prior to the
12 mo viral load assessment was 0.76 (0.73 to 0.80). Similar to
above, although this early adherence assessment was statisti-
cally signiﬁcantly less able to discriminate between those with
and without virologic failure at 12 mo when compared to the
adherence assessment using all 12 mo of adherence data (v2¼
46.0, p , 0.001), the AUC was similar to that resulting from
evaluation of the change in the CD4 count over the ﬁrst 12
mo of cART (0.76 for adherence measured over a 3 mo period
ending approximately 3 months prior to the 12 mo viral load
assessment versus 0.75 for CD4 change calculated over the
entire 12 months; v2¼ 0.39, p . 0.5). Use of days (rather than
months) did not signiﬁcantly alter the results (unpublished
data).
Adherence and CD4 Counts Combined
Positive predictive values (PPVs) and the proportions of
patients with virologic failure meeting each combined
criterion are shown in Table 6. At 6 mo, combined criteria
did not signiﬁcantly increase PPVs above that resulting from
adherence alone. For example, although a CD4 count
decrease from pretreatment values and adherence , 50%
at 6 mo increased the point estimate for PPV compared to
the adherence level with the highest PPV at 6 mo (, 50%,
PPV ¼ 87% [77%–93%], Table 3), the conﬁdence intervals
overlapped and the sensitivity for virologic failure decreased
(from 28% [22%–34%] to 12% [8%–17%]). Similar results
Figure 5. Scatter Plot of CD4 Count Change (cells/ll) at 12 Months after
Starting cART for Patients with and without Virologic Failure
doi:10.1371/journal.pmed.0050109.g005
Figure 6. ROC Curve for Adherence and CD4 Count Change when Used
to Identify Patients with Virologic Failure at 6 Months after cART
Initiation
Green and orange dots are observed adherence and CD4þ T cell count
change values, respectively. Thus, the graphs represent the sensitivity
and specificity that would result if each observed adherence or CD4þ T
cell count change value were used as a diagnostic test for current
virologic failure. The AUC was 0.79 (95% CI 0.76–0.83) for adherence and
0.68 (95% CI 0.64–0.72) for CD4 count change (p, 0.001, Chi-square
test).
doi:10.1371/journal.pmed.0050109.g006
Figure 7. ROC Curve for Adherence and CD4 Count Change when Used
to Identify Patients with Virologic Failure at 12 Months after cART
Initiation
Green and orange dots are observed adherence and CD4þ T cell count
change values, respectively. Thus, the graphs represent the sensitivity
and specificity that would result if each observed adherence or CD4þ T
cell count change value were used as a diagnostic test for current
virologic failure. The AUC was 0.85 (95% CI 0.82–0.88) for adherence and
0.75 (95% CI 0.72–0.79) for CD4 count change (p, 0.001, Chi-square
test).
doi:10.1371/journal.pmed.0050109.g007
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were seen at 12 mo (Table 6). For example, an adherence level
with the highest PPV at 6 mo (, 50%, Table 3) at 12 mo
resulted in a PPV of 88% (79%–93%), which was increased by
addition of a CD4 count decrease, but the conﬁdence
intervals overlapped and the sensitivity for virologic failure
signiﬁcantly decreased (from 37% [30%–43%] to 18% [14%–
24%]).
Negative predictive values (NPVs) and the proportions of
patients without virologic failure meeting each combined
criterion are shown in Table 7. Use of an adherence threshold
alone of 100% at both 6 and 12 mo resulted in NPVs of 91%
(88%–93%) and 94% (91%–97%), respectively. Furthermore,
66% (61%–70%) and 42% (38%–46%) of all patients without
virologic failure met this criterion at the 6- and 12-mo visits,
respectively. Two criteria, adherence  70% or  80% and a
CD4 count increase of  50 cells/ll at 6 mo maintained the
point estimate for NPV above 90% while increasing the
proportion of patients meeting that criterion at 6 mo (Table
7). At 12 mo, several criteria that maintained NPVs at or
above 94% while signiﬁcantly increasing the proportion of
patients meeting that criterion were identiﬁed (indicated by
footnotes in the ‘‘12 Mo’’ column in Table 7).
Table 2. Test Characteristics for CD4 Cell Count Changes for Identifying Patients with Virologic Failure after Initiating cART when
Assessed at 6 or 12 Months
Assessment
Point
Cutoff for CD4 Cell
Count Change (cells/ll)
AUC (95% CI) p-Valuea Sensitivity Specificity PPV NPV Percentage of
Virologic
Failures Missed
Percentage with
Regimen Changes
Despite Suppressed
Viral Loads
At 6 mo
(n ¼ 958)
Decrease to pretreatment
levels or below
0.58 (0.55–0.61) Reference 23% 93% 52% 79% 77% 7%
All CD4 counts , 100 0.56 (0.54–0.59) . 0.5 23% 93% 52% 79% 77% 7%
, 25b 0.61 (0.58–0.65) 0.005 34% 89% 51% 81% 66% 11%
, 50b 0.62 (0.58–0.65) 0.023 41% 82% 43% 81% 59% 18%
, 100b 0.63 (0.59–0.66) 0.029 62% 64% 36% 84% 38% 36%
At 12 mo
(n ¼ 872)
Decrease to pretreatment
levels or below
0.62 (0.59–0.65) Reference 29% 94% 64% 79% 71% 6%
All CD4 counts , 100 0.57 (0.54–0.59) 0.03 20% 96% 64% 77% 80% 4%
, 25b 0.66 (0.62–0.69) 0.001 40% 91% 62% 81% 60% 9%
, 50b 0.68 (0.64–0.71) , 0.001 49% 87% 57% 83% 51% 13%
, 100b 0.68 (0.64–0.72) 0.002 62% 73% 46% 73% 38% 27%
ap-Values are adjusted for multiple comparisons using Sidak’s method, and are for comparisons of the AUCs at each CD4 cell count change cutoff to the reference of a CD4 cell count drop
to pretreatment levels or below.
bIncreases of ,25, 50, or 100 cells/ll had greater overall accuracy than the two WHO-recommended criteria at 6 and 12 mo, but were not significantly different from each other (all p-
values . 0.4 for pairwise comparisons of AUCs).
doi:10.1371/journal.pmed.0050109.t002
Table 3. Test Characteristics for Adherence Levels for Identifying Patients with Virologic Failure after Initiating cART when Assessed at
6 or 12 Months
Assessment
Point
Adherence
Level
AUC (95% CI) p-Valuea Sensitivity Specificity PPV NPV Percentage of
Virologic
Failures Missed
Percentage with
Regimen Changes
Despite Suppressed
Viral Loads
At 6 mo
(n ¼ 958)
, 50% 0.63 (0.60–0.66) Reference 28% 99% 87% 81% 72% 1%
, 60% 0.68 (0.64–0.71) 0.01 39% 96% 75% 83% 61% 4%
, 70% 0.70 (0.66–0.73) , 0.001 51% 88% 59% 85% 49% 12%
, 80%b 0.74 (0.71–0.78) , 0.001 63% 86% 59% 88% 37% 14%
, 90% 0.71 (0.67–0.74) , 0.001 81% 60% 40% 91% 19% 40%
, 100% 0.71 (0.67–0.74) , 0.001 81% 60% 40% 91% 19% 40%
At 12 mo
(n ¼ 872)
, 50% 0.67 (0.64–0.71) Reference 37% 98% 88% 81% 63% 2%
, 60% 0.68 (0.64–0.71) . 0.5 41% 94% 72% 82% 59% 6%
, 70% 0.70 (0.67–0.73) . 0.5 48% 91% 66% 83% 52% 9%
, 80% 0.70 (0.67–0.74) . 0.5 55% 86% 58% 84% 45% 14%
, 90% b 0.76 (0.73–0.79) , 0.001 84% 68% 49% 92% 16% 32%
, 100% 0.67 (0.65–0.70) . 0.5 93% 42% 36% 94% 7% 58%
ap-Values are adjusted for multiple comparisons using Sidak’s method, and are for comparisons of the AUCs at each adherence level cutoff to the reference of a adherence level , 50%..
bAdherence , 80% and , 90% outperformed all other adherence values at 6 and 12 mo, respectively (p , 0.05 for all pairwise comparisons).
doi:10.1371/journal.pmed.0050109.t003
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Discussion
These results demonstrate that adherence levels, as
estimated by pharmacy claims data, can be at least as accurate
as CD4 count changes for detection of virologic failure
among patients receiving cART. This ﬁnding was consistent
when evaluating patients at two time points during the ﬁrst
year and after initial virologic suppression, and was not
dependent on the level of viremia used to deﬁne virologic
failure. Because cART scale-up guidelines for resource-
limited settings suggest use of CD4 count monitoring after
cART initiation [7], these ﬁndings are relevant to ongoing
antiretroviral treatment efforts in resource-limited settings.
A clinical implication of these results is that systematic
monitoring of pharmacy reﬁll adherence should be consid-
ered as an alternative to CD4 count monitoring for
identiﬁcation of patients with a high probability of virologic
failure. As shown, the ROC curve analyses indicate that given
a ﬁxed level of sensitivity, speciﬁcity resulting from monitor-
Table 4. Characteristics of Patients with and without Breakthrough Viremia after Initial Virologic Suppression on NNRTI-Based cART
(n ¼1,101)
Characteristic Group Virologic Failurea (n ¼ 151) Adjusted Odds Ratio (95% CI)
Sex Female 106 of 728 (15%) Reference
Male 45 of 373 (12%) 0.77 (0.53–1.12)
Age , 35 y 67 of 456 (15%) Reference
. 35 y 84 of 645 (13%) 0.84 (0.60–1.20)
Treatment naı¨ve Yes 128 of 979 (13%) Reference
No 23 of 122 (19%) 1.54 (0.94–2.51)
Baseline CD4 count  100 cells/ll 53 of 357 (15%) Reference
. 100 cells/ll 98 of 744 (13%) 1.26 (0.87–1.83)
Baseline HIV-1 RNA level  100,000 copies/ml 68 of 516 (13%) Reference
. 100,000 copies/ml 83 of 585 (14%) 1.08 (0.76–1.54)
Adherence level . 90% 55 of 669 (8%) Reference
 90% 96 of 432 (22%) 3.24 (2.26–4.65)
CD4 count drop to pretreatment levels or below No 128 of 1,047 (12%) Reference
Yes 23 of 54 (43%) 5.87 (3.27–10.51)
Follow-up CD4 , 50% maximum therapy level No 129 of 1,062 (12%) Reference
Yes 22 of 39 (56%) 9.03 (4.62–17.63)
aDefined as a viral load . 1,000 copies/ml after initial virologic suppression.
doi:10.1371/journal.pmed.0050109.t004
Table 5. Test Characteristics for CD4 Cell Count Changes and Adherence Levels for Identifying Patients with Breakthrough Virologic
Failure after Initial Response to cART (n¼1,101)
Criteria to Define
Virologic Failure
AUC (95% CI) p-Valuea Sensitivity Specificity PPV NPV Percentage of
Virologic
Failures Missed
Percentage with
Regimen Changes
Despite Suppressed
Viral Loads
CD4 decrease to pretreatment
levels or below
0.56 (0.53–0.59) Reference 15% 97% 43% 88% 85% 3%
CD4 decrease to level  50%
of maximum on treatment value
0.56 (0.53–0.59) . 0.5 15% 98% 52% 88% 85% 2%
CD4 decrease to level  40% of
maximum on treatment value
0.59 (0.56–0.63) 0.40 23% 96% 47% 89% 77% 4%
CD4 decrease to level  30% of
maximum on treatment valueb
0.62 (0.58–0.66) 0.020 32% 91% 38% 90% 68% 9%
CD4 decrease to level  20% of
maximum on treatment valueb
0.64 (0.60–0.68) , 0.001 44% 85% 31% 90% 56% 15%
Adherence ,50%c 0.57 (0.54–0.60) . 0.5 17% 97% 49% 88% 83% 3%
Adherence ,60% 0.60 (0.57–0.64) 0.43 25% 96% 48% 89% 75% 4%
Adherence ,70% 0.63 (0.59–0.67) 0.04 34% 92% 40% 90% 66% 8%
Adherence ,80% 0.63 (0.59–0.67) 0.09 42% 84% 29% 90% 58% 16%
Adherence ,90% 0.64 (0.60–0.68) 0.02 64% 64% 22% 92% 36% 36%
Adherence ,100% 0.59 (0.55–0.63) . 0.5 72% 46% 18% 92% 28% 54%
ap-Values are adjusted for multiple comparisons, and are for comparisons of the AUCs at each CD4 cell count or adherence cutoff to the reference of a CD4 cell count drop to pretreatment
levels or below.
bCD4 cell count decreases of .20% and .30% were significantly more accurate than other CD4 cell count criteria (p , 0.006 for all AUC comparisons), but were not different from each
other (p . 0.1).
cAll adherence values except at levels of , 60% were more accurate than either WHO-advocated CD4 count criteria.
doi:10.1371/journal.pmed.0050109.t005
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ing adherence will tend to be higher than that seen with
WHO-advocated CD4 count changes in the ﬁrst year and
approximately equivalent thereafter. This translates into
fewer patients with unnecessary regimen changes and fewer
virologic failures missed. For example, based on the analysis
of this cohort, if an adherence level of , 50% was used in
place of a CD4 count decrease to pretreatment levels or
below to identify virologic failure at 12 mo, the proportion of
unnecessary regimen changes would decrease (from 6% to
2%), and the proportion of virologic failures identiﬁed would
increase (from 28% to 37%). Furthermore, the fact that the
ROC areas for adherence measured months prior to a viral
load were relatively consistent with adherence assessments
and CD4 count changes performed later indicates that
adherence monitoring may be a useful approach for early
identiﬁcation of patients at high risk of future virologic
failure. This result is intuitive given the causal pathway
wherein poor adherence leads to virologic failure, which
leads in turn to immunologic decline [30]. Importantly,
however, poor adherence does not invariably result in
virologic failure [12–14]. Therefore, although detection of a
CD4 count decline would be unlikely to lead to a treatment
change in the ﬁrst year of cART, detection of adherence
lapses early may enable targeted adherence interventions
capable of preventing virologic failure [31,32] and prolonging
time on less-expensive ﬁrst-line cART. This contrasts with
CD4 count monitoring, which inherently identiﬁes virologic
failure after it has already occurred.
How should these data be used clinically? For clinics that
do not have CD4 counts or viral load monitoring capabilities,
pharmacy-based adherence monitoring should be adopted in
order to identify patients in need of adherence interventions.
Alternatively, adherence monitoring could be used to pursue
focused virologic or genotypic testing in settings where these
assays are available to some but not all, or after cheaper assays
become more widely available. The high NPVs resulting from
adherence monitoring indicate that adherence data can be
used to identify a relatively large group of patients who have a
low probability of virologic failure. Moreover, combining
adherence data with a simple CD4 count threshold (e.g.,
adherence , 90% and no CD4 count decrease at 12 mo),
could identify a subset of patients at such low risk of virologic
failure that virologic monitoring might be postponed. For
example, clinics able to perform viral load assessments in all
patients routinely could use adherence monitoring to guide
decision-making on timing of these tests. For example,
patients with perfect adherence and a CD4 count increase
of more than 100 cells/ll at 6 mo could have their viral load
assessed at 12 mo, or patients with adherence , 90% at 3 mo
could have their viral load assessed at 6 mo (e.g., after an early
adherence intervention). Although pharmacy reﬁll adherence
monitoring appears useful in these types of approaches,
ultimately monitoring strategies must consider the resources
available to the setting and should be informed by formal
cost-effectiveness studies.
Our inclusion criteria were strict, yet comparison of
patients included and excluded indicated that there were
no clinically meaningful differences in the baseline CD4
counts or viral loads. Moreover, the estimates of the accuracy
of CD4 count changes for virologic failure documented in
Table 6. PPVs of CD4 Count and Adherence Data Combined for Virologic Failure at 6 and 12 Months
Adherence CD4 Count Change
(cells/ll)
6 Months (n ¼ 958) 12 Months (n ¼ 872)
PPV (95% CI) Percentage with Virologic
Failure Meeting
Criterion (95% CI)
PPV (95% CI) Percentage with Virologic
Failure Meeting
Criterion (95% CI)
Adherence , 50% AND CD4 count decrease 93% (78%–99%) 12% (8%–17%) 95% (85%–99%) 18% (14%–24%)
CD4 increase , 25 89% (77%–96%) 18% (13%–23%) 93% (83%–98%) 23% (18%–29%)
CD4 increase , 50 86% (75%–94%) 22% (17%–28%) 91% (82%–97%) 28% (22%–34%)
CD4 increase , 100 84% (74%–90%) 32% (26%–39%) 90% (82%–96%) 32% (27%–39%)
Adherence , 60% AND CD4 count decrease 88% (64%–99%) 6% (4%–10%) 96% (86%–100%) 21% (16%–27%)
CD4 increase , 25 89% (77%–96%) 18% (13%–23%) 94% (85%–98%) 27% (21%–33%)
CD4 increase , 50 86% (75%–94%) 22% (17%–28%) 91% (83%–96%) 32% (26%–39%)
CD4 increase , 100 84% (74%–90%) 32% (26%–39%) 88% (80%–94%) 38% (32%–45%)
Adherence , 70% AND CD4 count decrease 89% (76%–96%) 17% (13%–23%) 95% (86%–99%) 24% (19%–31%)
CD4 increase , 25 83% (72%–91%) 25% (19%–31%) 93% (84%–97%) 32% (26%–39%)
CD4 increase , 50 78% (67%–86%) 29% (24%–36%) 90% (82%–95%) 38% (32%–45%)
CD4 increase , 100 74% (65%–81%) 43% (36%–49%) 85% (78%–91%) 46% (40%–53%)
Adherence , 80% AND CD4 count decrease 89% (76%–96%) 17% (13%–23%) 88% (78%–95%) 27% (21%–33%)
CD4 increase , 25 83% (72%–91%) 25% (19%–31%) 87% (79%–93%) 36% (30%–43%)
CD4 increase , 50 78% (67%–86%) 29% (24%–36%) 84% (76%–90%) 43% (37%–50%)
CD4 increase , 100 74% (65%–81%) 43% (36%–49%) 80% (73%–86%) 52% (46%–59%)
Adherence , 90% AND CD4 count decrease 66% (53%–77%) 20% (15%–25%) 83% (72%–90%) 27% (21%–33%)
CD4 increase , 25 64% (55%–73%) 29% (24%–36%) 82% (74%–89%) 37% (30%–43%)
CD4 increase , 50 61% (52%–69%) 36% (30%–42%) 78% (70%–85%) 45% (38%–51%)
CD4 increase , 100 53% (47%–60%) 52% (46%–59%) 73% (65%–79%) 57% (50%–63%)
Adherence , 100% AND CD4 count decrease 66% (53%–77%) 20% (15%–25%) 74% (64%–83%) 28% (22%–34%)
CD4 increase , 25 64% (55%–73%) 29% (24%–36%) 75% (66%–82%) 38% (32%–45%)
CD4 increase , 50 61% (52%–69%) 36% (30%–42%) 69% (61%–76%) 47% (40%–53%)
CD4 increase , 100 53% (47%–60%) 52% (46%–59%) 59% (52%–65%) 60% (53%–66%)
doi:10.1371/journal.pmed.0050109.t006
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this study concur with results presented from two other
settings [17,33]. We do not therefore feel that signiﬁcant bias
resulted from patient exclusions. However, although the
NNRTI-based cART regimens used and the immunologic
responses were similar to those found in several other cohorts
[17,21–23], this study was performed in a private-care setting,
so the potential generalizability of the results should also be
considered. For example, the adherence calculation was
based on claims, and patients receiving cART at free clinics
do not generally submit pharmacy claims. However, dates of
actual reﬁlls were used to calculate intervals between
dispensations. For this reason, an adherence calculation such
as that performed here should be feasible in large public
clinics where medications are often free. Furthermore,
pharmacy claims data may overestimate true adherence
because patients may not take all claimed medications.
However, the goal of this study was to determine if pharmacy
reﬁll data, as observed in clinical practice, could be used as a
test for virologic failure, and to compare this approach with
CD4 count levels, which also suffer from measurement error
and biological variability. In addition, alternative measures of
adherence, including subjective measures that were not
available to us [34,35], should be examined, as should
accuracy of this approach in patients on non-NNRTI-based
cART. Finally, the AUC for adherence assessments for
virologic failure was lower in the analysis of breakthrough
viremia compared to the AUCs for adherence assessments for
virologic failure done at 6 and 12 months after HAART
initiation. One possible explanation of this ﬁnding is that
selection of resistance mutations, caused by subtle lapses in
adherence not captured by pharmacy claims data, caused a
decrease in the diagnostic accuracy of adherence over time.
Patterns of adherence may inﬂuence the risk of virologic
failure differently when patients initiate therapy compared to
when their viral loads are suppressed below quantiﬁable
levels. Since nearly 25% of all drug resistance occurs in
patients with high levels of adherence [36], it would have been
interesting to explore the relationship between virologic
failure, resistance, and diagnostic accuracy of adherence in
this setting, but genotyping data were unavailable.
Although CD4 counts inform when to start antiretroviral
therapy and when to stop prophylaxis for opportunistic
infections, these data indicate that guidelines such as those
produced by the WHO [7] for monitoring patients receiving
cART in resource-limited settings should include consider-
ation of an adherence-based monitoring approach.
Furthermore, future research should examine this ap-
proach in other settings with variable testing capabilities and
should identify and address possible barriers to operational-
izing systematic monitoring of adherence. For example, a
requirement of adherence monitoring based on pharmacy
records is ready access to drug reﬁll information as well as
conversion of these data into an adherence metric at the time
a patient is seen. Provision of adherence data to patients at
Table 7. NPVs of CD4 Count and Adherence Data Combined for Virologic Failure at 6 and 12 Months
Adherence CD4 Count Change
(cells/ll)
6 Months (n ¼ 958) 12 Months (n ¼ 872)
NPV (95% CI) Percentage with Suppressed
Viral Loads Meeting
Criterion (95% CI)
NPV (95% CI) Percentage with Suppressed
Viral Loads Meeting
Criterion (95% CI)
Adherence ¼ 100% AND CD4 increase .100 93% (89%–95%) 39% (35%–43%) 95% (91%–98%) 30% (27%–34%)
CD4 increase .50 92% (89%–94%) 50% (46%–54%) 95% (92%–98%) 36% (33%–40%)
CD4 increase .25 92% (89%–94%) 55% (51%–59%) 95% (92%–98%) 38% (34%–42%)
No CD4 decrease 92% (89%–94%) 57% (53%–60%) 95% (92%–98%) 40% (36%–43%)
Adherence  90% AND CD4 increase .100 93% (89%–95%) 39% (35%–43%) 93% (90%–96%) 49% (45%–53%)
CD4 increase .50 92% (89%–94%) 50% (46%–54%) 94% (91%–96%)b 59% (55%–63%)b
CD4 increase .25 92% (89%–94%) 55% (51%–59%) 93% (91%–96%)b 62% (58%–66%)b
No CD4 decrease 92% (89%–94%) 57% (53%–60%) 95% (92%–98%)b 65% (61%–68%)b
Adherence  80% AND CD4 increase .100 90% (87%–93%) 54% (51%–58%) 92% (89%–94%) 59% (55%–63%)
CD4 increase .50 90% (87%–92%)a 71% (67%–74%)a 94% (89%–94%) 70% (67%–74%)
CD4 increase .25 89% (87%–92%) 77% (74%–80%) 91% (88%–93%) 74% (70%–77%)
No CD4 decrease 88% (86%–91%) 80% (76%–82%) 91% (88%–93%) 76% (73%–79%)
Adherence  70% AND CD4 increase .100 90% (87%–93%) 54% (51%–58%) 91% (88%–93%) 64% (60%–67%)
CD4 increase .50 90% (87%–92%)a 71% (67%–74%)a 90% (87%–92%) 76% (72%–79%)
CD4 increase .25 89% (87%–92%) 77% (74%–80%) 89% (87%–92%) 80% (76%–83%)
No CD4 decrease 88% (86%–91%) 80% (76%–82%) 89% (86%–91%) 82% (79%–85%)
Adherence  60% AND CD4 increase .100 89% (85%–91%) 60% (57%–64%) 90% (87%–93%) 68% (64%–71%)
CD4 increase .50 88% (85%–90%) 78% (75%–81%) 89% (86%–92%) 80% (77%–83%)
CD4 increase .25 87% (85%–90%) 85% (82%–87%) 88% (86%–91%) 84% (81%–87%)
No CD4 decrease 86% (84%–89%) 88% (85%–90%) 87% (84%–90%) 87% (84%–90%)
Adherence  50% AND CD4 increase .100 87% (84%–90%) 63% (59%–66%) 88% (85%–91%) 72% (69%–76%)
CD4 increase .50 85% (82%–87%) 81% (78%–84%) 86% (83%–88%) 86% (83%–88%)
CD4 increase .25 85% (82%–87%) 88% (86%–91%) 85% (82%–88%) 90% (87%–92%)
No CD4 decrease 81% (78%–83%) 92% (90%–94%) 84% (81%–87%) 93% (90%–95%)
aThese criteria maintained the point estimate for negative predictive value for virologic failure at 6 months above 90% while increasing the proportion of patients meeting that criterion
compared to use of either adherence or CD4 counts alone.
bThese criteria maintained negative predictive values for virologic failure at 12 months at or above 93% while significantly increasing the proportion of patients meeting that criterion
compared to use of either adherence or CD4 counts alone.
doi:10.1371/journal.pmed.0050109.t007
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the point of care, however, could be either simple or more
complex. In Botswana, for example, patients present to
providers with a paper pharmacy card on which dates of
cART dispensation (and pill counts) are noted. Providers
conceptually can calculate adherence directly using these
cards. A more complex approach for clinics with computers
would be to link pharmacy and patient care records
electronically, so that a program would automatically supply
the pharmacy reﬁll adherence. The ability of adherence to
identify patients at high risk of virologic failure early and to
provide data on the behavior on which providers often wish
to intervene should be considered a reason for clinics to
organize these data in a way that can be used in simple
algorithmic approaches to patient care.
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Editors’ Summary
Background. Globally, more than 30 million people are infected with the
human immunodeficiency virus (HIV), the cause of acquired immunode-
ficiency syndrome (AIDS). Combinations of antiretroviral drugs that hold
HIV in check (viral suppression) have been available since 1996.
Unfortunately, most of the people affected by HIV/AIDS live in
developing countries and cannot afford these expensive drugs. As a
result, life expectancy has plummeted and economic growth has
reversed in these poor countries since the beginning of the AIDS
pandemic. Faced with this humanitarian crisis, the lack of access to HIV
treatment was declared a global health emergency in 2003. Today,
through the concerted efforts of governments, international organiza-
tions, and funding bodies, about a quarter of the HIV-positive people in
developing and transitional countries who are in immediate need of life-
saving, combination antiretroviral therapy (cART) receive the drugs they
need.
Why Was This Study Done? To maximize the benefits of cART, health-
care workers in developing countries need simple, affordable ways to
monitor viral suppression in their patients—a poor virologic response to
cART can lead to the selection of drug-resistant HIV, rapid disease
progression, and death. In developed countries, virologic response is
monitored by measuring the number of viral particles in patients’ blood
(viral load) but this technically demanding assay is unavailable in most
developing countries. Instead, the World Health Organization recom-
mends that CD4þ T cell (CD4) counts be used to monitor patient
responses to cART in resource-limited settings. HIV results in loss of CD4
cells (a type of immune system cell), so a drop in a patient’s CD4 count
often indicates virologic failure (failure of treatment to suppress the
virus). However, falling CD4 counts are often a result of virologic failure
and therefore monitoring CD4 counts for drops is unlikely to prevent
virologic failure from occurring. Rather, falling CD4 counts are often used
only to guide a change to new medicines, which may be even more
expensive or difficult to take. On the other hand ‘‘adherence lapses’’—
the failure to take cART regularly—often precede virologic failure, so
detecting them early provides an opportunity for improvement in
adherence that could prevent virologic failure. Because clinics that
dispense cART routinely collect data that can be used to calculate
adherence, in this study the researchers investigate whether assessing
adherence might provide an alternative, low-cost way to monitor and
predict virologic failure among HIV-infected adults on cART.
What Did the Researchers Do and Find? The Aid for AIDS Disease
Management Program provides cART to medical insurance fund
subscribers in nine countries in southern Africa. Data on claims for
antiretroviral drugs made through this program, plus CD4 counts
assessed at about 6 or 12 months after initiating cART, and viral load
measurements taken within 45 days of a CD4 count, were available for
nearly 2,000 HIV-positive adults who had been prescribed a combination
of HIV drugs including either efavirenz or nevirapine. The researchers
defined adherence as the number of months of cART claims submitted
divided by the number of complete months between cART initiation and
the last pharmacy refill before a viral load assessment was performed.
Virologic failure was defined in two ways: as a viral load of more than
1,000 copies per ml of blood 6 or 12 months after cART initiation, or as a
rebound of viral load to similar levels after a previously very low reading
(breakthrough viremia). The researchers’ statistical analysis of these data
shows that at 6 and 12 months after initiation of cART, adherence levels
indicated virologic failure more accurately than CD4 count changes. For
breakthrough viremia, both measurements were equally accurate.
Adherence levels during the first 3 months of cART predicted virologic
failure at 6 months as accurately as did CD4 count changes since cART
initiation. Finally, the combination of adherence levels and CD4 count
changes accurately identified patients at very low risk of virologic failure.
What Do These Findings Mean? These findings suggest that adherence
assessments (based in this study on insurance claims for pharmacy refills)
can identify the patients on cART who are at high and low risk of
virologic failure at least as accurately as CD4 counts. In addition, they
suggest that adherence assessments could be used for early identi-
fication of patients at high risk of virologic failure, averting the health
impact of treatment failure and the cost of changing to second-line drug
regimens. Studies need to be done in other settings (in particular, in
public clinics where cART is provided without charge) to confirm the
generalizability of these findings. These finding do not change that fact
that monitoring CD4 counts plays an important role in deciding when to
start cART or indicating when cART is no longer protecting the immune
system. But, write the researchers, systematic monitoring of adherence
to cART should be considered as an alternative to CD4 count monitoring
in patients who are receiving cART in resource-limited settings or as a
way to direct the use of viral load testing where feasible.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050109.
 This study is discussed further in a PLoS Medicine Perspective by David
Bangsberg
 Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
 HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including an article about adherence to antiretroviral therapy
 Information is available from Avert, an international AIDS charity, on
HIV and AIDS in Africa and on providing AIDS drug treatment for
millions
 The World Health Organization provides information about universal
access to HIV treatment (in several languages) and on its
recommendations for antiretroviral therapy for HIV infection in
adults and adolescents
 The US Centers for Disease Control and Prevention also provides
information on global efforts to deal with the HIV/AIDS pandemic (in
English and Spanish)
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